Skip to content
Poster

Effect of Tolvaptan in combination with rapamycin in a rat model of polycystic kidney disease

Background & Aim:

Polycystic kidney disease (PKD) is a congenital fibrocystic disorder where cysts are forming within the kidney and liver, causing declined kidney function and can eventually lead to chronic kidney disease (CKD). Animal models with improved clinical translatability can optimally inform about potential clinical efficacy of novel drug candidates for PKD. The PCK rat is an established genetic model of PKD with natural history and renal histologic abnormalities resembling the human disease. Here, we characterized the effect of the vasopressin V2 receptor antagonist Tolvaptan, the only approved drug treatment for PKD, in combination with rapamycin, a compound known to slow cystogenesis in the PCK rat model.

Subjects
3D imagingPolycystic kidney disease (PCK) ratChronic kidney diseaseBody weightRatKidney morphometryLight sheet fluorescence microscopy (LSFM)Liver morphometryVasopressin v2 receptor (V2R)Urine biochemistryRapamycinTolvaptan
Related resources
Poster
Ultrasound and 3D imaging characterisation of a rat model of polycystic kidney disease

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top